The BPaL TB regimen patent India decision has removed one barrier to generic competition for a key drug-resistant tuberculosis treatment. According to press reports, the Indian Patent Office rejected the non-profit TB Alliance’s application for a patent on BPaL, a combination of bedaquiline, pretomanid and linezolid, in an order dated 27 October 2026. The reported grounds include lack of novelty, no inventive step, non-patentability and insufficient disclosure. This explainer sets out what was decided, who challenged the application, what it may mean for patients and manufacturers, and what remains unknown, including whether an appeal will follow.
BPaL TB regimen patent India: key takeaways
- The Indian Patent Office has reportedly rejected TB Alliance’s patent application for the BPaL combination in an order dated 27 October 2026.
- Reported grounds: lack of novelty, no inventive step, non-patentability and insufficient disclosure.
- Pre-grant oppositions were filed in July 2020 by patient and public-health groups, according to press reports.
- TB Alliance did not attend the final hearings and had not commented, so its position and any appeal are unknown.
- A rejection removes one patent barrier but does not by itself guarantee generic supply or lower prices.
What is BPaL, and why the BPaL TB regimen patent India ruling matters
BPaL combines three antibacterial medicines: bedaquiline, pretomanid and linezolid. A related regimen, BPaLM, adds moxifloxacin. They are used against drug-resistant forms of tuberculosis, where standard first-line medicines no longer work. Treatment courses for drug-resistant TB have historically been long and burdensome, so shorter, all-oral regimens are a priority for public health. The World Health Organization provides background on TB and its treatment. Because the regimen is built from existing medicines, the dispute concerns whether the combination and its use deserve a separate patent.
What the Patent Office decided in the BPaL TB regimen patent India case
Press reports say the order rejected the application for lack of novelty and inventive step, and also on grounds of non-patentability and insufficient disclosure. They describe the order as invoking provisions of the Patents Act including Sections 3(d), 3(e) and 3(i), which restrict patents on certain new forms of known substances, mere admixtures and methods of treatment. The reports do not name the controller who decided the matter, and we have not seen the order itself, so the grounds are given as reported. Indian patent filings are tracked by the Indian Patent Office.
Who challenged the BPaL TB regimen patent India application
According to press reports, pre-grant oppositions were filed in July 2020 under Section 25(1) of the Patents Act by groups including the Delhi Network of Positive People, Sankalp Rehabilitation Trust, Third World Network, Lawyers Collective and the MSF Access Campaign, with individuals including Eldred Tellis and Ganesh Acharya named. The oppositions reportedly argued that the combination, and its use for a shorter regimen, had already been disclosed in studies published in 2015. A pre-grant opposition lets third parties argue against a patent before it is granted.
TB Alliance and the BPaL TB regimen patent India outcome
TB Alliance is a non-profit product-development organisation focused on TB medicines; its work is described on its website. Press reports say it did not attend the final hearings and had not responded to requests for comment. We therefore do not know whether it will appeal, what it argued in the proceedings, or how it views the decision. Readers should treat the rejection as a first-instance outcome that may still be contested.
What the BPaL TB regimen patent India decision could mean for generics
Patents are one of several factors that decide whether a medicine is made and sold by multiple manufacturers. Without a patent on the combination, Indian companies would face one fewer legal barrier to producing it, subject to rights over individual components, regulatory approval and commercial decisions. Reports note a 2023 rejection of a patent extension request for bedaquiline in India, and say BPaL patents have reportedly been granted in 11 countries, among them Russia, South Africa, Indonesia and Kazakhstan, running to 2036 in some cases. Prices, supply and timing are not addressed in the sources and should not be assumed.
India’s TB burden and the BPaL TB regimen patent India debate
India accounts for roughly a quarter of the world’s TB cases. Press reports cite about 2.71 million cases in 2024, or 187 per 100,000 people, as a WHO estimate. They also say more than 15,000 patients in India’s national TB programme have started BPaLM. Those figures help explain why access and affordability are central to the debate. More coverage is in our Pharmaceutical section.
Market context from Acumen Research and Consulting
Acumen Research and Consulting’s Infectious Disease Market report values the global market at USD 26.4 billion in 2022 and projects more than USD 50.7 billion by 2032, a CAGR of 6.9% for 2023 to 2032. It attributes about 40% of the market to North America and projects Asia Pacific growth of around 8% a year. The report mentions TB only in passing and its growth figures do not fully reconcile, so these numbers give broad context and not a TB-specific forecast.
Timeline of the BPaL TB regimen patent India dispute
- 2015: studies on the combination are published; opponents say they disclosed it.
- July 2020: pre-grant oppositions are filed.
- 27 October 2026: the Patent Office order rejecting the application, as reported.
- 29 October 2026: press coverage of the decision.
General background: how patent oppositions work
In India, anyone can file a pre-grant opposition on stated grounds, such as lack of novelty or inventive step. The controller considers the opposition and the applicant’s response before deciding whether to grant the patent. A rejected applicant can usually appeal. Section 3(d) is often discussed in pharmaceutical cases because it limits patents on new forms of known substances unless they show significantly improved efficacy.
Our analysis of the BPaL TB regimen patent India decision
In our assessment, the BPaL TB regimen patent India ruling is significant mainly for the precedent it sets on combination regimens built from known medicines, and for public-health groups that have argued such combinations should remain open to competition. Whether it changes access depends on appeals, component patents, approvals and manufacturing decisions.
What is not disclosed about the BPaL TB regimen patent India ruling
- The full text of the order and the name of the deciding controller.
- Whether TB Alliance will appeal.
- Which companies, if any, plan to make the regimen, and at what price.
Risks and caveats
This article is based on press reports of the order and has not reviewed the order. It is news reporting and not legal or medical advice, and patients should follow their doctors’ guidance.
What to watch next on the BPaL TB regimen patent India case
- Any appeal or statement from TB Alliance.
- Publication of the full order.
- Generic manufacturer announcements and tender prices.
Questions readers are asking about the BPaL TB regimen patent India decision
Will the regimen become cheaper? That is possible but not guaranteed. Does the ruling affect treatment today? The reports do not say it changes current treatment. Is the decision final? Not necessarily, because an appeal may be filed.
FAQ
What is BPaL?
A regimen of bedaquiline, pretomanid and linezolid used for drug-resistant TB.
Who rejected the patent?
The Indian Patent Office, according to press reports.
When was the order dated?
27 October 2026, as reported.
How we reported this: we relied on press reports of the decision, public pages from the WHO, TB Alliance and the Indian Patent Office, and the Acumen Research and Consulting report cited above. We have not seen the order. Last updated 30 October 2026. This is news reporting and not advice.